Previous studies indicated that DOX application significantly decreased the body weight in cancer patients [43], but intriguingly, we found that cardiac-specific overexpression of FNDC5 attenuated DOX-induced body weight loss in mice, which raises the possibility for its clinical use (Fig. 1d). The gene discussed is FNDC5; the disease is cancer.